Wells Fargo
HZNP

Wells Fargo’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Wells Fargo’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-43,803
Closed -$5.07M – 7861
2023
Q3 		$5.07M Sell
43,803
-10,385
-19% -$1.12M ﹤0.01% 2096
2023
Q2 		$5.57M Sell
54,188
-228,778
-81% -$24.1M ﹤0.01% 2052
2023
Q1 		$30.9M Buy
282,966
+130,345
+85% +$14.4M 0.01% 892
2022
Q4 		$17.4M Sell
152,621
-55,977
-27% -$4.65M 0.01% 1196
2022
Q3 		$12.9M Sell
208,598
-72,990
-26% -$5.1M ﹤0.01% 1333
2022
Q2 		$22.5M Sell
281,588
-94,207
-25% -$8.92M 0.01% 1072
2022
Q1 		$39.5M Sell
375,795
-4,797
-1% -$467K 0.01% 892
2021
Q4 		$41M Sell
380,592
-1,499,821
-80% -$164M 0.01% 866
2021
Q3 		$206M Buy
1,880,413
+387,995
+26% +$40.3M 0.05% 398
2021
Q2 		$140M Buy
1,492,418
+144,289
+11% +$13.3M 0.03% 524
2021
Q1 		$124M Sell
1,348,129
-62,987
-4% -$5.32M 0.03% 563
2020
Q4 		$103M Buy
1,411,116
+465,229
+49% +$34.6M 0.02% 627
2020
Q3 		$73.5M Buy
945,887
+390,965
+70% +$26.9M 0.02% 685
2020
Q2 		$30.8M Buy
554,922
+231,846
+72% +$9.92M 0.01% 1104
2020
Q1 		$9.57M Sell
323,076
-9,151
-3% -$310K ﹤0.01% 1704
2019
Q4 		$12M Sell
332,227
-38,289
-10% -$1.17M ﹤0.01% 1832
2019
Q3 		$10.1M Buy
370,516
+106,953
+41% +$2.77M ﹤0.01% 1932
2019
Q2 		$6.34M Buy
263,563
+10,082
+4% +$256K ﹤0.01% 2354
2019
Q1 		$6.7M Sell
253,481
-20,600
-8% -$488K ﹤0.01% 2274
2018
Q4 		$5.36M Sell
274,081
-37,078
-12% -$727K ﹤0.01% 2376
2018
Q3 		$6.09M Buy
311,159
+23,856
+8% +$454K ﹤0.01% 2499
2018
Q2 		$4.76M Sell
287,303
-279,648
-49% -$4.26M ﹤0.01% 2734
2018
Q1 		$8.05M Buy
566,951
+186,210
+49% +$2.75M ﹤0.01% 2197
2017
Q4 		$5.56M Sell
380,741
-75,428
-17% -$1.06M ﹤0.01% 2488
2017
Q3 		$5.78M Buy
456,169
+90,692
+25% +$1.15M ﹤0.01% 2391
2017
Q2 		$4.34M Sell
365,477
-133,310
-27% -$1.66M ﹤0.01% 2565
2017
Q1 		$7.37M Buy
498,787
+55,678
+13% +$902K ﹤0.01% 2122
2016
Q4 		$7.17M Buy
443,109
+72,812
+20% +$1.32M ﹤0.01% 2108
2016
Q3 		$6.71M Buy
370,297
+49,766
+16% +$972K ﹤0.01% 2058
2016
Q2 		$5.28M Buy
320,531
+76,212
+31% +$1.23M ﹤0.01% 2274
2016
Q1 		$4.05M Sell
244,319
-65,683
-21% -$1.15M ﹤0.01% 2448
2015
Q4 		$6.72M Sell
310,002
-132,707
-30% -$2.58M ﹤0.01% 2144
2015
Q3 		$8.77M Sell
442,709
-367,712
-45% -$11.6M ﹤0.01% 1899
2015
Q2 		$28.2M Buy
810,421
+155,878
+24% +$4.76M 0.01% 1137
2015
Q1 		$17M Buy
654,543
+599,111
+1,081% +$11M 0.01% 1450
2014
Q4 		$714K Buy
55,432
+5,760
+12% +$72.1K ﹤0.01% 3728
2014
Q3 		$610K Sell
49,672
-34,900
-41% -$406K ﹤0.01% 3769
2014
Q2 		$1.34M Buy
84,572
+5,158
+6% +$73.6K ﹤0.01% 3300
2014
Q1 		$1.2M Buy
+79,414
New +$897K ﹤0.01% 3362

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Wells Fargo's HZNP Position: Q4 2023 in Review

Wells Fargo sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 43,803 shares — an estimated $5.07M sold.

Wells Fargo first reported a position in HZNP in Q1 2014 and held it in 39 quarters. The position peaked at $206M in Q3 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Wells Fargo reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Wells Fargo sold 43,803 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $5.07M.
  • Wells Fargo first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 39 quarters.
  • Wells Fargo's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $206M in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Wells Fargo's 13F filing for Q4 2023, filed 9 Feb 2024.